Diagnostic and Treatment Advances in COVID-19 and SARS-CoV-2 | Book Publisher International

 

The ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has been a formidable global challenge. As yet, there are very few drugs to treat this infection and no vaccine is currently available. It has gradually become apparant that coronavirus disease 2019 (COVID-19) is not a simple disease involving a single organ; rather, many vital organs and systems are affected. 1. Established based on coronavirus control method, constructed the carbon nanotube thermal conversion effect and nonspecific antigen presentation nano light vaccine, can be used in a short time of carbon nanotube heat resonance make the virus infection local rapid warming to 57 degrees Celsius, efficient kill virus, at the same time using nanotube carrier of SARS-CoV-2 specific RBD combined with virus S protein, competitive inhibition virus and the host cell membrane ACE 2 receptor, reduce the infection rate, activate the body's T cell immunity, stimulate the corresponding antibodies, to neutralize the invading virus immune response. At the same time, the concentration control of nanomaterials can effectively prevent the immune storm caused by the excessive activation of T cells and reduce the immune damage. 2. It demonstrated the importance of the endothelial system as an defense against viral infection, and maintaining the integrity of endothelial morphology is an important measure to inhibit the host of viral infection. 3. It is demonstrated that phospholipid S1P inside and outside the cell membrane can effectively maintain cell membrane homeostasis, repair the damaged cell membrane in time, and moderate S1P concentration is an important method to protect the damage of the endothelial system, so as to effectively inhibit SARS-CoV-2 infection.4 It discusses that the combination of non-homologous multiple convalescent plasma-derived mAbs is an effective way to solve the low efficiency of antibody neutralization and the limitation of antibody specificity.

Author(s) Details:

Jianshe Yang,
Shanghai Tenth People’s Hospital of Tongji University School of Medicine, Gansu Medical College, China.

Zhongwei Lv,
Shanghai Tenth People’s Hospital of Tongji University School of Medicine, China.

Qiang Wang,
Gansu Medical College, China.

Rongzhi Zhang,
Lanzhou University Second Hospital, China.

Chengyou Jia,
State Grid Gansu Power Transmission and Transformation Engineering Company, China.

Xiaoying Zhang,
Shanghai Tenth People’s Hospital of Tongji University School of Medicine, China.

Dan Li,
Sun Yat-sen Hospital of Sun Yat-sen University, China.

Siyang Zhou,
Gansu Medical College, China.

Fenfen Zhang,
Gansu Medical College, China.

Xuchang Zhang,
Second Affiliated Hospital of the Chinese University of Hong Kong, China.

Xinhuang Yao,
Second Affiliated Hospital of the Chinese University of Hong Kong, China.

Shixin Lei,
Gansu Medical College, China.

Jinyu Tian,
Gansu Medical College, China.


Please see the link here: https://stm.bookpi.org/DTACSC/article/view/9548